Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00131742
Status:
COMPLETED
Last Update Posted:
2015-05-12
First Post:
2005-08-18
Brief Title:
Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A Phase III Randomized Double Blind Trial of LdT Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B
Status:
COMPLETED
Status Verified Date:
2015-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is being conducted to compare the effectiveness and safety of telbivudine LdT and lamivudine in Chinese adults
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None